Trending...
- Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling
- Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
- Veterans Day 2025: Virginia Veterans Can Claim Free Words of Veterans Book Vouchers
SHANGHAI, May 28, 2023 ~ Abbisko Therapeutics Co., Ltd. has announced that the updated results of their Phase Ib study of their CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT") will be released at the 2023 American Society of Clinical Oncology ("ASCO") annual meeting to be held in Chicago, USA from June 2 to June 6, 2023.
The data demonstrates the excellent antitumor efficacy and safety profile of Pimicotinib in the treatment of patients with advanced TGCT and will be presented with the title of "EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE" in a poster presentation with the poster Bd# of "493".
The most remarkable result is the objective response rate (ORR) of the 50 mg QD dose group of Pimicotinib (ABSK021), which reached 77.4% (24/31), including two complete responses (CR) and 22 partial responses (PR). Additionally, 87.5% (21/24) of patients with objective response were observed within the first 25 weeks. Furthermore, Pimicotinib also presented apparent advantages in terms of safety profile.
More on illi News
Currently, Pexidartinib developed by Daiichi Sankyo is the only drug approved for the treatment of TGCT in the global market. However, it has been given a "black box warning" by the FDA due to potential risk of fatal liver damage and its objective response rate is only 38%. Despite this, Daiichi Sankyo achieved sales of approximately US$40 million in the global market with Pexidartinib. CICC predicts that the global market for TGCT could amount to around 1 billion US dollars.
In comparison to Pexidartinib from Daiichi Sankyo, Abbisko's Pimicotinib shows better efficacy and safety in treating TGCT and is expected to become a best-in-class drug. If approved for use on TGCT in 2025 with a market penetration rate of 20%, its peak sales are estimated to reach 3.14 billion yuan (after risk adjustment) with listing price reference to Pexidartinib at $250,000 per year.
The data demonstrates the excellent antitumor efficacy and safety profile of Pimicotinib in the treatment of patients with advanced TGCT and will be presented with the title of "EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE" in a poster presentation with the poster Bd# of "493".
The most remarkable result is the objective response rate (ORR) of the 50 mg QD dose group of Pimicotinib (ABSK021), which reached 77.4% (24/31), including two complete responses (CR) and 22 partial responses (PR). Additionally, 87.5% (21/24) of patients with objective response were observed within the first 25 weeks. Furthermore, Pimicotinib also presented apparent advantages in terms of safety profile.
More on illi News
- 10 Essential Tips for Maximizing Value When Choosing Your Orlando Wedding Venue
- Americans Are Trading Offices for Beaches: How Business Ownership Enables the Ultimate Location Freedom
- Boston Industrial Solutions' Natron® DC Series Ink Has Had an Upgrade!
- Colony Ridge Proudly Supports the All Ears! 2025 Sporting Clays Tournament
- Jacob Emrani Nominated for LA Executive Award
Currently, Pexidartinib developed by Daiichi Sankyo is the only drug approved for the treatment of TGCT in the global market. However, it has been given a "black box warning" by the FDA due to potential risk of fatal liver damage and its objective response rate is only 38%. Despite this, Daiichi Sankyo achieved sales of approximately US$40 million in the global market with Pexidartinib. CICC predicts that the global market for TGCT could amount to around 1 billion US dollars.
In comparison to Pexidartinib from Daiichi Sankyo, Abbisko's Pimicotinib shows better efficacy and safety in treating TGCT and is expected to become a best-in-class drug. If approved for use on TGCT in 2025 with a market penetration rate of 20%, its peak sales are estimated to reach 3.14 billion yuan (after risk adjustment) with listing price reference to Pexidartinib at $250,000 per year.
Filed Under: Business
0 Comments
Latest on illi News
- Taikan's T-V856S VMC Earns Prestigious 2025 Vogel Global Pioneer Award
- Flick Truck Accident Law Joins the Commercial Vehicle Safety Alliance to Strengthen Truck Safety Advocacy
- PebblePad Announces Global Partnership with Inside Higher Ed and Times Higher Education
- Passion Struck Network Debuts: A Creator-First Platform for Purpose-Driven Podcasting and Human Impact
- The Aligned Woman Is It Well With Your Soul
- Jonathan Malveaux Named Newest Member of Forbes Business Council
- NFL Midseason 2025: Who's for Real and Who's Faking It?
- Silver Ball, Golden Heart: Dallas-Area Pinball Wizards Flip for Charity at Side Quest Arcade
- Sweet Beginnings: Sugar Queen Dessert Shop Opens in the Colony Ridge Community
- Mayor Brandon Johnson Launches Next Phase Of The Protecting Chicago Budget Tour
- World Record Established: Million-Dollar Bilibin Screen Sells at Shapiro Auctions
- Lawproactive Launches Next-Generation CRM, Marrying Data and Location with Geo-Optimized Funnels for Attorney Lead Generation
- POWER SOLUTIONS N.V. Partners with ENERGY33 LLC to Deliver a 40.5 MW Temporary Power Project for ECUACORRIENTE S.A. in Ecuador
- Axis International Invites Inventors to Turn Ideas Into Market-Ready Products
- Pioneering the Future of Human-Computer Interaction Through AI-Powered Neural Input Technology: Wearable Devices Ltd. (N A S D A Q: WLDS)
- Isringhausen Imports Named Best Auto Dealer — Again
- Epic Pictures Group Sets North American Release Date for the Action Thriller LOST HORIZON
- HR Soul Consulting Recognized as a 2025 Inc. Power Partner Award Winner for the Fourth Consecutive Year
- Due Date Performance Matters. Especially Dealing with Suppliers
- Industrial Steam Install at Crider Foods Facility